Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin

Neuropsychopharmacology

Volumn 30, Issue 10, 2005, Pages 1883-1894

  Lee, Paul R ^a   Brady, Dana L ^a   Shapiro, Robert A ^b   Dorsa, Daniel M ^b   Koenig, James I ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Amygdala; Hypothalamus; NMDA receptor; Oxytocin; Rats; Schizophrenia; Social interaction

Indexed keywords

MESSENGER RNA; MOLECULAR MARKER; NEUROPEPTIDE; OXYTOCIN; PHENCYCLIDINE; SODIUM CHLORIDE; VASOPRESSIN;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; ASSAY; BEHAVIOR DISORDER; BEHAVIORAL SCIENCE; CONTROLLED STUDY; GENE EXPRESSION; HORMONE RECEPTOR INTERACTION; HYPOTHALAMUS; INFUSION; INJECTION; LIGHT DARK CYCLE; MALE; NONHUMAN; OPEN FIELD BEHAVIOR; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION;

ADAPTATION, PHYSIOLOGICAL; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXPLORATORY BEHAVIOR; GENE EXPRESSION REGULATION; HALLUCINOGENS; IN SITU HYBRIDIZATION; INTERPERSONAL RELATIONS; MALE; OXYTOCIN; PHENCYCLIDINE; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; SOCIAL BEHAVIOR DISORDERS; TIME FACTORS; VASOPRESSINS;

EID: 21744439972     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300722     Document Type: Article

References (72)

1. Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, Hetrick WP et al (1996). Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16: 19-30.
2. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M et al (2001). A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 158: 1305-1313.
3. Bale TL, Pedersen CA, Dorsa DM (1995). CNS oxytocin receptor mRNA expression and regulation by gonadal steroids. Adv Exp Med Biol 395: 269-280.
4. Beckmann H, Lang RE, Gattaz WF (1985). Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology 10: 187-191.
5. Bernstein HG, Jirikowski GF, Heinemann A, Baumann B, Hornstein C, Danos P et al (2000). Low and infrequent expression of nitric oxide synthase/NADPH-diaphorase in neurons of the human supraoptic nucleus: a histochemical study. J Chem Neuroanatomy 20: 177-183.
6. Bernstein HG, Stanarius A, Baumann B, Henning H, Krell D, Danos P et al (1998). Nitric oxide synthase-containing neurons in the human hypothalamus: reduced number of immunoreactive cells in the paraventricular nucleus of depressive patients and schizophrenics. Neuroscience 83: 867-875.
7. Bowers G, Cullinan WE, Herman JP (1998). Region-specific regulation of glutamic acid decarboxylase (GAD) mRNA expression in central stress circuits. J Neurosci 18: 5938-5947.
8. Braff DL, Geyer MA (1990). Sensorimotor gating and schizophrenia. Human and animal model studies. Arch Gen Psychiatry 47: 181-188.
9. Brambilla F, Aguglia E, Massironi R, Maggioni M, Grillo W, Castiglioni R et al (1986). Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration. Neuropsychobiology 15: 114-121.
10. Brambilla F, Bondiolotti GP, Maggioni M, Sciascia A, Grillo W, Sanna F et al (1989). Vasopressin (DDAVP) therapy in chronic schizophrenia: effects on negative symptoms and memory. Neuropsychobiology 20: 113-119.
11. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter Jr WT (1998). Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 155: 751-760.
12. Bujanow W (1974). Is oxytocin an anti-schizophrenic hormone? Can J Psychiatry 19: 323.
13. Corrigan PW, Reinke RR, Landsberger SA, Charate A, Toombs GA (2003). The effects of atypical antipsychotic medications on psychosocial outcomes. Schizophrenia Res 63: 97-101.
14. Drago F, Caldwell JD, Pedersen CA, Continella G, Scapagnini U, Prange Jr AJ (1986). Dopamine neurotransmission in the nucleus accumbens may be involved in oxytocin-enhanced grooming behavior of the rat. Pharmacol Biochem Behav 24: 1185-1188.
15. Elman I, Lukas S, Shoaf SE, Rott D, Adler C, Breier A (2003). Effects of acute metabolic stress on the peripheral vasopressinergic system in schizophrenia. J Psychopharmacol 17: 317-323.
16. Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002). D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophrenia Res 56: 19-23.
17. Feifel D, Priebe K (2001). Vasopressin-deficient rats exhibit sensorimotor gating deficits that are reversed by subchronic haloperidol. Biol Psychiatry 50: 425-433.
18. Feifel D, Reza T (1999). Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology (Berlin) 141: 93-98.
19. Ferguson JN, Young LJ, Insel TR (2002). The neuroendocrine basis of social recognition. Front Neuroendocrinol 23: 200-224.
20. File SE, Hyde JR (1979). A test of anxiety that distinguishes between the actions of benzodiazepines and those of other minor tranquilisers and of stimulants. Pharmacol Biochem Behav 11: 65-69.
21. Finlay JM (2001). Mesoprefrontal dopamine neurons and schizophrenia: role of developmental abnormalities. Schizophrenia Bull 27: 431-442.
22. Francis DD, Young LJ, Meaney MJ, Insel TR (2002). Naturally occurring differences in maternal care are associated with the expression of oxytocin and vasopressin (V1a) receptors: gender differences. J Neuroendocrinol 14: 349-353.
23. Frederiksen SO, Ekman R, Gottfries CG, Widerlov E, Jonsson S (1991). Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr Scand 83: 273-277.
24. Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, Tamminga CA (2000). Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: effects of schizophrenia. Am J Psychiatry 157: 1141-1149.
25. Glovinsky D, Kalogeras KT, Kirch DG, Suddath R, Wyatt RJ (1994). Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophrenia Res 11: 273-276.
26. Gurtman CG, Morley KC, Li KM, Hunt GE, McGregor IS (2002). Increased anxiety in rats after 3, 4-methylenedioxymethamphetamine: association with serotonin depletion. Eur J Pharmacol 446: 89-96.
27. Hanania T, Hillman GR, Johnson KM (1999). Augmentation of locomotor activity by chronic phencyclidine is associated with an increase in striatal NMDA receptor function and an upregulation of the NR1 receptor subunit. Synapse 31: 229-239.
28. Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC (2004). High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia. Biol Psychiatry 55: 165-171.
29. Humphries C, Mortimer A, Hirsch S, de Belleroche J (1996). NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 7: 2051-2055.
30. lager AC, Kirch DG, Bigelow LB, Karson CN (1986). Treatment of schizophrenia with a vasopressin analogue. Am J Psychiatry 143: 375-377.
31. Insel TR, Young LJ (2000). Neuropeptides and the evolution of social behavior. Curr Opin Neurobiol 10: 784-789.
32. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148: 1301-1308.
33. Jentsch JD, Taylor JR, Elsworth JD, Redmond Jr DE, Roth RH (1999). Altered frontal cortical dopaminergic transmission in monkeys after subchronic phencyclidine exposure: involvement in frontostriatal cognitive deficits. Neuroscience 90: 823-832.
34. Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997). Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17: 92-99.
35. Koenig JI, Elmer GI, Shepard PD, Lee PR, Mayo C, Joy B et al (2005). Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia. Behav Brain Res 156: 251-261.
36. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51: 199-214.
37. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995). Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13: 9-19.
38. Lee PR, Brady D, Koenig JI (2003). Corticosterone alters N-methyl-D-aspartate receptor subunit mRNA expression before puberty. Mol Brain Res 115: 55-62.
39. Legros JJ, Gazzotti C, Carvelli T, Franchimont P, Timsit-Berthier M, von Frenckell R et al (1992). Apomorphine stimulation of vasopressin- and oxytocin-neurophysins. Evidence for increased oxytocinergic and decreased vasopressinergic function in schizophrenics. Psychoneuroendocrinology 17: 611-617.
40. Lijam N, Paylor R, McDonald MP, Crawley JN, Deng CX, Herrup K et al (1997). Social interaction and sensorimotor gating abnormalities in mice lacking Dvl1. Cell 90: 895-905.
41. Linkowski P, Geenen V, Kerkhofs M, Mendlewicz J, Legros JJ (1984). Cerebrospinal fluid neurophysins in affective illness and in schizophrenia. Eur Arch Psychiatry Neurol Sci 234: 162-165.
42. Lipska BK, Weinberger DR (2000). To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23: 223-239.
43. Long JM, LaPorte P, Paylor R, Wynshaw-Boris A (2004). Expanded characterization of the social interaction abnormalities in mice lacking Dvl1. Genes Brain Behav 3: 51-62.
44. Mai JK, Berger K, Sofroniew MV (1993). Morphometric evaluation of neurophysin-immunoreactivity in the human brain: pronounced inter-individual variability and evidence for altered staining patterns in schizophrenia. J Hirnforsch 34: 133-154.
45. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
46. Mansbach RS, Geyer MA (1989). Effects of phencyclidine and phencyclidine biologs on sensorimotor gating in the rat. Neuropsychopharmacology 2: 299-308.
47. McCarthy MM, McDonald CH, Brooks PJ, Goldman D (1996). An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiol Behav 60: 1209-1215.
48. Miyakawa T, Leiter LM, Gerber DJ, Gainetdinov RR, Sotnikova TD, Zeng H et al (2003). Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci USA 100: 8987-8992.
49. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999). Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98: 427-436.
50. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T et al (1999). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20: 106-118.
51. Noda Y, Mamiya T, Furukawa H, Nabeshima T (1997). Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice. Eur J Pharmacol 324: 135-140.
52. Noda Y, Yamada K, Furukawa H, Nabeshima T (1995). Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia. Br J Pharmacol 116: 2531-2537.
53. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Coordinates 2nd edn. Academic Press: Orlando, FL.
54. Qiao H, Noda Y, Kamei H, Nagai T, Furukawa H, Miura H et al (2001). Clozapine, but not haloperidol, reverses social behavior deficit in mice during withdrawal from chronic phencyclidine treatment. Neuroreport 12: 11-15.
55. Raskind MA, Courtney N, Murburg MM, Backus FI, Bokan JA, Ries RK et al (1987). Antipsychotic drugs and plasma vasopressin in normals and acute schizophrenic patients. Biol Psychiatry 22: 453-462.
56. Sams-Dodd F (1995). Distinct effects of d-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol 6: 55-65.
57. Sams-Dodd F (1997). Effect of novel antipsychotic drugs on phencyclidine-induced stereotyped behaviour and social isolation in the rat social interaction test. Behav Pharmacol 8: 196-215.
58. Sams-Dodd F (1998). Effects of diazepam, citalopram, methadone and naloxone on PCP-induced stereotyped behaviour and social isolation in the rat social interaction test. Neurosci Biobehav Rev 23: 287-293.
59. Sams-Dodd F, Lipska BK, Weinberger DR (1997). Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behavior in adulthood. Psychopharmacology (Berlin) 132: 303-310.
60. Sherman TG, Day R, Civelli O, Douglass J, Herbert E, Akil H et al (1988). Regulation of hypothalamic magnocellular neuropeptides and their mRNAs in the Brattleboro rat: coordinate responses to further osmotic challenge. J Neurosci 8: 3785-3796.
61. Sturgeon RD, Fessler RG, London SF, Meltzer HY (1982). Behavioral effects of chronic phencyclidine administration in rats. Psychopharmacology (Berlin) 76: 52-56.
62. Swenson KL, Badre SE, Morsette DJ, Sladek CD (1998). N-methyl-D-aspartic acid stimulation of vasopressin release: role in osmotic regulation and modulation by gonadal steroids. J Neuroendocrinol 10: 679-685.
63. Swerdlow NR, Braff DL, Taaid N, Geyer MA (1994). Assessing the validity of an animal model of deficient sensorimotor gating in schizophrenic patients. Arch Gen Psychiatry 51: 139-154.
64. Swerdlow NR, Caine SB, Geyer MA (1992). Regionally selective effects of intracerebral dopamine infusion on sensorimotor gating of the startle reflex in rats. Psychopharmacology 108: 189-195.
65. Szot P, Bale TL, Dorsa DM (1994). Distribution of messenger RNA for the vasopressin Via receptor in the CNS of male and female rats. Mol Brain Res 24: 1-10.
66. Tanaka K, Suzuki M, Sumiyoshi T, Murata M, Tsunoda M, Kurachi M (2003). Subchronic phencyclidine administration alters central vasopressin receptor binding and social interaction in the rat. Brain Res 992: 239-245.
67. Tsai G, Yang P, Chung LC, Lange N, Coyle JT (1998). D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 44: 1081-1089.
68. Uvnas-Moberg K (1998). Oxytocin may mediate the benefits of positive social interaction and emotions. Psychoneuroendocrinology 23: 819-835.
69. Uvnas-Moberg K, Alster P, Svensson TH (1992). Amperozide and clozapine but not haloperidol or raclopride increase the secretion of oxytocin in rats. Psychopharmacology 109: 473-476.
70. Varty GB, Geyer MA (1998). Effects of isolation rearing on startle reactivity, habituation, and prepulse inhibition in male Lewis, Sprague-Dawley, and Fischer F344 rats. Behav Neurosci 112: 1450-1457.
71. Wang C, Showalter VM, Hillman GR, Johnson KM (1999). Chronic phencyclidine increases NMDA receptor NR1 subunit mRNA in rat forebrain. J Neurosci Res 55: 762-769.
72. Witt DM, Winslow JT, Insel TR (1992). Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacol Biochem Behav 43: 855-861.